Showing 1681-1690 of 5643 results for "".
- Santen Announces Initiation of Phase 3 Clinical Program (SPECTRUM) Evaluating Glaucoma Treatment Omidenepag Isopropyl (DE-117)https://modernod.com/news/santen-announces-initiation-of-phase-3-clinical-development-program-spectrum-in-the-united-states-evaluating-omidenepag-isopropyl-de-117-for-the-treatment-of-glaucoma-or-ocular-hypertension/2479772/Santen announced the initiation of the pivotal phase 3 development program (SPECTRUM) in the United States, evaluating the investigational use of omidenepag isopropyl (DE-117), a selective agonist for the prostanoid receptor EP2, for the treatment of glaucoma or o
- Nicox Announces Last Patients Complete Final Visit in NCX 470 Phase 3 Mont Blanc Glaucoma Trialhttps://modernod.com/news/nicox-announces-last-patients-complete-final-visit-in-ncx-470-phase-3-mont-blanc-glaucoma-trial/2481100/Nicox announced that the last patients completed their final (3-month) visit in the Mont Blanc phase 3 clinical trial of NCX 470 0.1% for the lowering of IOP in patients with open-angle glaucoma or ocular hypertension. A total of
- Visual Clinic’s ‘Safe Visits’ Aims to Help Eye Care Clinics Comply with New Post-COVID-19 Protocolshttps://modernod.com/news/visual-clinics-safe-visits-aims-to-help-eye-care-clinics-comply-with-new-post-covid-19-protocols/2477921/Visual Clinic announced the launch of its Safe Visits application. The software module provides ophthalmology and optometry practices with a streamlined care process that safely and efficiently guides patients and staff through appointments in the post-COVID-19 environment, according to a company
- CMS Eases Requirements for COVID-19 Tests, Boosts Payments for Telephonic Visitshttps://modernod.com/news/cms-eases-requirements-for-covid-19-tests-boosts-payments-for-telephonic-visits/2477699/The Trump administration is easing requirements on testing for COVID-19 to make it easier to administer drive-thru and “parking lot” testing facilities, according to a FierceHealthcare
- Ora Names Gustavo De Moraes, MD, PHD, Chief Medical Officerhttps://modernod.com/news/ora-names-gustavo-de-moraes-md-phd-chief-medical-officer/2480622/Ora announced that distinguished op
- Conbercept Treatment of Wet AMD Completes 36-Week Primary Endpoint Visits of Phase 3 Trialhttps://modernod.com/news/conbercept-treatment-of-wet-amd-completes-36-week-primary-endpoint-visits-of-phase-3-trial/2478698/China-based Chengdu Kanghong Pharmaceutical Group announced a key development milestone of its key product conbercept last month. Kanghong is seeking global approval of conbercept by undertaking a multicenter, multinational, d
- Last Patient, Last Visit Completed in RegeneRx Phase 3 Dry Eye Clinical Trialhttps://modernod.com/news/last-patient-last-visit-completed-in-regenerx-phase-3-dry-eye-clinical-trial/2478508/RegeneRx Biopharmaceuticals announced that the final patient in its 700 subject, ARISE-3 phase 3 clinical trial for dry eye syndrome has completed treatment and follow-up. ARISE-3 is designed to assess the safety and efficacy of 0.1% RGN-259 eye drops compared to placebo after 2 weeks of
- American Academy of Ophthalmology Urges Members to Immediately Stop Routine Surgical and In-Office Visitshttps://modernod.com/news/american-academy-of-ophthalmology-urges-members-to-immediately-stop-routine-surgical-and-in-office-visits/2477412/Due to the COVID-19 pandemic, the American Academy of Ophthalmology (AAO) stated that all ophthalmologists cease providing any treatment other than urgent or emergent care immediately. The statement posted on the AAO website reads: “We now live and practice in a critically di
- Santen and Glaukos Enter into Collaboration and Distribution Agreement for Exclusive Distribution of the MicroShunt (DE-128) in the UShttps://modernod.com/news/santen-and-glaukos-enter-into-collaboration-and-distribution-agreement-for-exclusive-distribution-of-the-microshunt-de-128-in-the-us/2476507/Santen Pharmaceutical announced that its US subsidiary, Santen Inc., has entered into a multi-year agreement whereby Glaukos will become the exclusive distributor of the MicroShunt in the U.S. market. Financial
- AAO: Home OCT Device Improves Care for AMD Patients, Reduces Costs and Burdenhttps://modernod.com/news/aao-home-oct-device-improves-care-for-amd-patients-reduces-costs-and-burden/2482499/A newly approved home-based OCT device developed by Notel Vision is allowing patients to monitor their own eye health between appointments, providing physicians with crucial data without requiring in-office visits, according to an AAO news release. A study presented today at AAO 2024 suggest